HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M600229-MCP200v1 5/10/1840    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Villanueva, J. Articles by Tempst, P. Search for Related Content PubMed PubMed Citation Articles by Villanueva, J. Articles by Tempst, P. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:1840-1852, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Cancer

Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age^*,S

Josep Villanueva^,, Andrew J. Martorella^¶, Kevin Lawlor, John Philip, Martin Fleisher^||, Richard J. Robbins^¶,**, and Paul Tempst^,,

From the Protein Center, Molecular Biology Program, and Departments of ^¶ Medicine and ^|| Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 and ^** Department of Medicine, The Methodist Hospital, Houston, Texas 77030

Serum peptidomics is a special form of functional proteomics. The small number of blood proteins that are the source of most prominent peptides in human serum serve as a substrate pool for commonly occurring and/or cancer-derived proteases. Exoprotease activities in particular, when superimposed on the ex vivo coagulation and complement degradation pathways, contribute to generation of not only cancer-specific but also "cancer type"-specific serum peptides. Following development of a unique, semiautomated serum peptide profiling platform and after completing investigations to eliminate common experimental bias, we have now studied possible effects of gender and age on serum peptidomes of 200 healthy men and women, ages 20–80, and of 60 patients (30 men and 30 women) with metastatic thyroid carcinomas. Extensive MALDI-TOF MS and data analysis suggested negligible contributions of both age and gender to the serum peptidome patterns except that healthy men and women under 35 years, but not older individuals, could be distinguished with 70% accuracy. Considering the more advanced age of most patients, this finding is unlikely to interfere with peptidomics analysis of most cancers. By examining patient samples and age/gender-matched controls followed by variability analysis of either demographic or disease (versus control) groups, we could conclusively rule out demographic bias. An optimized, 12-peptide ion thyroid cancer signature was then developed, enabling classification of an independent validation set with 95% sensitivity and 95% specificity (binomial confidence intervals, 75.1–99.9%). Ten of these peptides had previously been assigned to signature patterns of other solid tumor cancers. One of the two newly discovered peptides was dehydro-Ala³-fibrinopeptide A. As we expand this study to include hundreds of thyroid cancer patients, the peptide signature will be adjusted, further validated, and then evaluated in a clinical setting used either independently or in combination with existing markers.

To whom correspondence may be addressed: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: p-tempst{at}mskcc.org

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Peccerella, N. Lukan, R. Hofheinz, D. Schadendorf, M. Kostrezewa, M. Neumaier, and P. Findeisen Endoprotease Profiling with Double-Tagged Peptide Substrates: A New Diagnostic Approach in Oncology Clin. Chem., February 1, 2010; 56(2): 272 - 280. [Abstract] [Full Text] [PDF]

				J. F. Timms, R. Cramer, S. Camuzeaux, A. Tiss, C. Smith, B. Burford, I. Nouretdinov, D. Devetyarov, A. Gentry-Maharaj, J. Ford, et al. Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer Clin. Chem., February 1, 2010; 56(2): 262 - 271. [Abstract] [Full Text] [PDF]

				G. M. Fiedler, A. B. Leichtle, J. Kase, S. Baumann, U. Ceglarek, K. Felix, T. Conrad, H. Witzigmann, A. Weimann, C. Schutte, et al. Serum Peptidome Profiling Revealed Platelet Factor 4 as a Potential Discriminating Peptide Associated with Pancreatic Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3812 - 3819. [Abstract] [Full Text] [PDF]

				T. Plavina, M. Hincapie, E. Wakshull, M. Subramanyam, and W. S. Hancock Increased Plasma Concentrations of Cytoskeletal and Ca2+-Binding Proteins and Their Peptides in Psoriasis Patients Clin. Chem., November 1, 2008; 54(11): 1805 - 1814. [Abstract] [Full Text] [PDF]

				J. Villanueva, A. Nazarian, K. Lawlor, S. S. Yi, R. J. Robbins, and P. Tempst A Sequence-specific Exopeptidase Activity Test (SSEAT) for "Functional" Biomarker Discovery Mol. Cell. Proteomics, March 1, 2008; 7(3): 509 - 518. [Abstract] [Full Text] [PDF]

				L. A. Liotta and E. F. Petricoin Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform Clin. Chem., January 1, 2008; 54(1): 3 - 5. [Full Text] [PDF]